GOLD 2017 treatment pathways in ‘real life’: An analysis of the DACCORD observational study

Respiratory Medicine

Volumn 131, Issue , 2017, Pages 77-84

  Worth, Heinrich ^a   Buhl, Roland ^b   Criée, Carl Peter ^c   Kardos, Peter ^d   Lossi, Nadine S ^e   Vogelmeier, Claus F ^f  

^a Praxis Drs Bily Kellermann   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c Evangelical Hospital Goettingen Weende   (Germany)

^d Group Practice and Allergy   (Germany)

^e Novartis Pharma GmbH   (Germany)

^f UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Bronchodilator agents; Drug therapy; Pulmonary disease, chronic obstructive

Indexed keywords

CORTICOSTEROID; GLYCOPYRRONIUM BROMIDE PLUS INDACATEROL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; GLYCOPYRRONIUM; INDACATEROL-GLYCOPYRRONIUM COMBINATION; INDAN DERIVATIVE; MUSCARINIC RECEPTOR BLOCKING AGENT; QUINOLONE DERIVATIVE;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE DURATION; DISEASE EXACERBATION; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; CLINICAL PATHWAY; COMBINATION DRUG THERAPY; DISEASE MANAGEMENT; GERMANY; INHALATIONAL DRUG ADMINISTRATION; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; PATHOPHYSIOLOGY; PRACTICE GUIDELINE;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; CRITICAL PATHWAYS; DISEASE MANAGEMENT; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; GERMANY; GLYCOPYRROLATE; HUMANS; INDANS; LONGITUDINAL STUDIES; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES;

EID: 85029716711     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2017.08.008     Document Type: Article

References (24)

1. Global Initiative for Chronic Obstructive Lung Disease, Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. www.goldcopd.org, 2017, Accessed date 21 December 2016.
2. Kardos, P., Vogelmeier, C., Buhl, R., Criée, C.-P., Worth, H., The prospective non-interventional DACCORD Study in the National COPD Registry in Germany: design and methods. BMC Pulm. Med., 15, 2015, 2, 10.1186/1471-2466-15-2.
3. Buhl, R., Criée, C.-P., Kardos, P., Vogelmeier, C., Lossi, N., Mailaender, C., Worth, H., A year in the life of German patients with COPD: the DACCORD observational study. Int. J. Chron. Obstruct. Pulmon. Dis. Vol. 11 (2016), 1639–1646, 10.2147/COPD.S112110.
4. Vogelmeier, C., Worth, H., Buhl, R., Criée, C.-P., Lossi, N.S., Mailänder, C., Kardos, P., “Real-life” inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD. Int. J. Chron. Obstruct. Pulmon. Dis. Vol. 12 (2017), 487–494, 10.2147/COPD.S125616.
5. Worth, H., Buhl, R., Criée, C.-P., Kardos, P., Mailänder, C., Vogelmeier, C., The “real-life” COPD patient in Germany: the DACCORD study. Respir. Med. 111 (2016), 64–71, 10.1016/j.rmed.2015.12.010.
6. Kardos, P., Vogelmeier, C., Worth, H., Buhl, R., Lossi, N.S., Mailänder, C., Criée, C.-P., A two-year evaluation of the “real life” impact of COPD on patients in Germany: the DACCORD observational study. Respir. Med. 124 (2017), 57–64, 10.1016/j.rmed.2017.02.007.
7. Maleki-Yazdi, M.R., Singh, D., Anzueto, A., Tombs, L., Fahy, W.A., Naya, I., Assessing short-term deterioration in maintenance-naïve patients with COPD receiving umeclidinium/vilanterol and tiotropium: a pooled analysis of three randomized trials. Adv. Ther. 33 (2016), 2188–2199, 10.1007/s12325-016-0430-6.
8. Troosters, T., Sciurba, F.C., Decramer, M., Siafakas, N.M., Klioze, S.S., Sutradhar, S.C., Weisman, I.M., Yunis, C., Tiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebo-controlled trial. Npj Prim. Care Respir. Med, 24, 2014, 14003, 10.1038/npjpcrm.2014.3.
9. Troosters, T., Celli, B.R., Lystig, T., Kesten, S., Mehra, S., Tashkin, D.P., Decramer, M., Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur. Respir. J. 36 (2010), 65–73, 10.1183/09031936.00127809.
10. Vogelmeier, C., Fabbri, L.M., Rabe, K.F., Beeh, K.-M., Schmidt, H., Metzdorf, N., Glaab, T., Effect of tiotropium vs. salmeterol on exacerbations: GOLD II and maintenance therapy naïve patients. Respir. Med. 107 (2013), 75–83, 10.1016/j.rmed.2012.09.015.
11. Decramer, M., Rossi, A., Lawrence, D., McBryan, D., Indacaterol therapy in patients with COPD not receiving other maintenance treatment. Respir. Med. 106 (2012), 1706–1714, 10.1016/j.rmed.2012.08.022.
12. Singh, D., Ferguson, G.T., Bolitschek, J., Grönke, L., Hallmann, C., Bennett, N., Abrahams, R., Schmidt, O., Bjermer, L., Tiotropium+olodaterol shows clinically meaningful improvements in quality of life. Respir. Med. 109 (2015), 1312–1319, 10.1016/j.rmed.2015.08.002.
13. Bateman, E.D., Chapman, K.R., Singh, D., D'Urzo, A.D., Molins, E., Leselbaum, A., Gil, E.G., Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respir. Res., 16, 2015, 92, 10.1186/s12931-015-0250-2.
14. Bateman, E.D., Ferguson, G.T., Barnes, N., Gallagher, N., Green, Y., Henley, M., Banerji, D., Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur. Respir. J. 42 (2013), 1484–1494, 10.1183/09031936.00200212.
15. Celli, B., Crater, G., Kilbride, S., Mehta, R., Tabberer, M., Kalberg, C.J., Church, A., Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest 145 (2014), 981–991, 10.1378/chest.13-1579.
16. Wedzicha, J.A., Banerji, D., Chapman, K.R., Vestbo, J., Roche, N., Ayers, R.T., Thach, C., Fogel, R., Patalano, F., Vogelmeier, C.F., Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N. Engl. J. Med. 374 (2016), 2222–2234, 10.1056/NEJMoa1516385.
17. Rossi, A., van der Molen, T., Del Olmo, R., Papi, A., Wehbe, L., Quinn, M., Lu, C., Young, D., Cameron, R., Bucchioni, E., Altman, P., INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD. Eur. Respir. J. 44 (2014), 1548–1556, 10.1183/09031936.00126814.
18. Magnussen, H., Disse, B., Rodriguez-Roisin, R., Kirsten, A., Watz, H., Tetzlaff, K., Towse, L., Finnigan, H., Dahl, R., Decramer, M., Chanez, P., Wouters, E.F.M., Calverley, P.M.A., Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N. Engl. J. Med. 371 (2014), 1285–1294, 10.1056/NEJMoa1407154.
19. Rossi, A., Guerriero, M., Corrado, A., on behalf of the OPTIMO/AIPO Study Group. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). Respir. Res., 15, 2014, 77, 10.1186/1465-9921-15-77.
20. Miller, J., Edwards, L.D., Agustí, A., Bakke, P., Calverley, P.M.A., Celli, B., Coxson, H.O., Crim, C., Lomas, D.A., Miller, B.E., Rennard, S., Silverman, E.K., Tal-Singer, R., Vestbo, J., Wouters, E., Yates, J.C., Macnee, W., Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir. Med. 107 (2013), 1376–1384, 10.1016/j.rmed.2013.05.001.
21. Rodríguez, L.A.G., Wallander, M.-A., Martín-Merino, E., Johansson, S., Heart failure, myocardial infarction, lung cancer and death in COPD patients: a UK primary care study. Respir. Med. 104 (2010), 1691–1699, 10.1016/j.rmed.2010.04.018.
22. Barr, R.G., Celli, B.R., Mannino, D.M., Petty, T., Rennard, S.I., Sciurba, F.C., Stoller, J.K., Thomashow, B.M., Turino, G.M., Comorbidities, patient knowledge, and disease management in a national sample of patients with COPD. Am. J. Med. 122 (2009), 348–355, 10.1016/j.amjmed.2008.09.042.
23. Brusselle, G., Price, D., Gruffydd-Jones, K., Miravitlles, M., Keininger, D.L., Stewart, R., Baldwin, M., Jones, R.C., The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int. J. Chron. Obstruct. Pulmon. Dis. 10 (2015), 2207–2217, 10.2147/COPD.S91694.
24. Dransfield, M.T., Bailey, W., Crater, G., Emmett, A., O'Dell, D.M., Yawn, B., Disease severity and symptoms among patients receiving monotherapy for COPD. Prim. Care Respir. J. 20 (2011), 46–53, 10.4104/pcrj.2010.00059.